Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.67 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Analyst Ratings Send Ripples Through Markets: Sarepta's Resilience vs. Pinterest's Plunge
The financial markets are a complex ecosystem, constantly reacting to a myriad of inputs, from macroeconomic data to geopolitical shifts. Among the most closely watched catalysts are the pronouncements... 
Via MarketMinute
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
 
Via Benzinga
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
Sarepta Therapeutics Inc. (NASDAQ: SRPT) experienced a dramatic downturn in its stock valuation today, November 4, 2025, following the announcement of disappointing results from a pivotal late-stage... 
Via MarketMinute
Topics Death
Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comeback
Via Stocktwits
Which stocks are experiencing notable movement on Tuesday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Gold Falls Over 1%; Uber Shares Decline After Q3 Results
 
Via Benzinga
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness. 
Via Benzinga
Tuesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Earnings Scheduled For November 3, 2025
 
Via Benzinga
A Peek at Sarepta Therapeutics's Future Earnings
 
Via Benzinga
Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It
Enough though Sarepta shares are crashing, "Pharma Bro" Martin Shkreli says he still likes the stock. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Tuesday's pre-market session: top gainers and losers
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Dow Futures Edge Lower On Pullback Fears: PLTR, SRPT, TSLA, AMD Among Stocks To Watch
While Dow Jones futures were down by 0.72% at the time of writing, the S&P 500 futures fell 1.02%. 
Via Stocktwits
Topics ETFs Stocks
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Why
Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update on its ESSENCE study. 
Via Benzinga
These stocks are moving in today's after hours session
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests
Sarepta stock crashed Monday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
From Sarepta Therapeutics, Inc.
Via Business Wire
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. 
Via Benzinga
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
Tradr Unleashes 2X Single-Stock Gold ETFs, Reshaping Short-Term Gold Investment Landscape
New York, NY – October 23, 2025 – Tradr, a prominent innovator in the Exchange-Traded Fund (ETF) market, has today significantly expanded its product suite with the launch of nine new single-stock 2X... 
Via MarketMinute
Topics Artificial Intelligence Derivatives ETFs
Tradr Launches 9 Single-Stock 2X ETFs With First-Of-Its-Kind OpenDoor, Gold And AI Exposure
The new ETFs include the first-of-their-kind gold and AI plays, giving traders targeted exposure without using margin or complex options. 
Via Benzinga
Topics Artificial Intelligence ETFs
Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
Funds seek to provide 200% long exposure on a variety of industry leaders 
Via Stocktwits
Topics ETFs
What's Going On Sarepta Stock On Wednesday?
Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.